首页> 外文期刊>Journal of Clinical Medicine Research >Depressor and Anti-Inflammatory Effects of Angiotensin II Receptor Blockers in Metabolic and/or Hypertensive Patients With Coronary Artery Disease: A Randomized, Prospective Study (DIAMOND Study)
【24h】

Depressor and Anti-Inflammatory Effects of Angiotensin II Receptor Blockers in Metabolic and/or Hypertensive Patients With Coronary Artery Disease: A Randomized, Prospective Study (DIAMOND Study)

机译:代谢性和/或高血压性冠状动脉疾病患者中血管紧张素II受体阻滞剂的降压和抗炎作用:一项随机,前瞻性研究(DIAMOND研究)

获取原文
           

摘要

Background: We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective, randomized clinical trial.Methods: Forty-four hypertensive patients who had coronary artery disease (CAD) were enrolled. We randomly assigned patients to changeover from their prior angiotensin II receptor blockers (ARBs) to either azilsartan or olmesartan, and followed the patients for 12 weeks.Results: Office systolic blood pressure (SBP) in the azilsartan group was significantly decreased after 12 weeks. SBP and diastolic blood pressure (DBP) after 12 weeks in the azilsartan group were significantly lower than those in the olmesartan group. The percentage of patients who reached the target BP at 12 weeks (78%) in the azilsartan group was significantly higher than that at 12 weeks (45%) in the olmesartan group. There were no significant changes in pentraxin-3, high-sensitively C-reactive protein or adiponectin in blood after 12 weeks in either group. Although serum levels of creatinine (Cr) in the azilsartan group significantly increased, these changes were within the respective normal range.Conclusion: In conclusion, the ability of azilsartan to reduce BP may be superior to that of prior ARBs with equivalent safety in hypertensive patients with CAD.J Clin Med Res. 2016;8(10):743-748doi: http://dx.doi.org/10.14740/jocmr2675w
机译:背景:我们在一项前瞻性随机临床试验中比较了阿齐沙坦和奥美沙坦的疗效和安全性。方法:招募了44例患有冠心病(CAD)的高血压患者。我们随机分配患者从先前的血管紧张素II受体阻滞剂(ARBs)转换为阿齐沙坦或奥美沙坦,并随访患者12周。结果:阿齐沙坦组的办公室收缩压(SBP)在12周后显着降低。阿齐沙坦组12周后的SBP和舒张压(DBP)显着低于奥美沙坦组。阿齐沙坦组在12周时达到目标BP的患者百分比(78%)显着高于奥美沙坦组在12周时达到目标BP的患者百分比(45%)。两组在12周后血液中的pentraxin-3,高敏C反应蛋白或脂联素均无显着变化。尽管阿齐沙坦组的血清肌酐(Cr)水平显着升高,但这些变化均在各自的正常范围内。结论:总之,在高血压患者中,阿齐沙坦降低BP的能力可能优于先前的ARB,具有同等的安全性与CAD.J Clin Med Res。 2016; 8(10):743-748doi:http://dx.doi.org/10.14740/jocmr2675w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号